PhaseV vs Aleph Alpha

Side-by-side comparison of AI visibility scores, market position, and capabilities

PhaseV

EmergingBioTech

AI Clinical Trial Platform

Raised $50M Series A (May 2025) co-led by Accel and Insight Partners. Cuts trial costs 50%, enrollment 40%, duration 40%. 40+ pharma sponsors. 7 of world's top pharma companies as partners.

About

PhaseV is an AI clinical trial platform that uses predictive analytics to optimize trial design, site selection, patient enrollment, and protocol adherence — delivering dramatic efficiency improvements over traditional trial execution. The company raised $50 million in Series A financing in May 2025 co-led by Accel and Insight Partners, and entered 2026 with 40+ global pharmaceutical sponsors as customers including 7 of the world's top pharmaceutical companies.

Full profile

Aleph Alpha

EmergingAI Infra

Sovereign AI

Aleph Alpha raised €500M+ and pivoted to sovereign AI solutions for European governments, positioning as the leading provider of GDPR-compliant, EU-hosted AI infrastructure for regulated industries.

About

Aleph Alpha is a German AI company building sovereign AI infrastructure for European governments and enterprises that require data sovereignty, GDPR compliance, and AI hosted within EU borders. Its Pharia AI platform provides LLM capabilities deployed on-premises or in EU data centers, serving German federal ministries, European defense agencies, and regulated industries including banking, healthcare, and legal services.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.